DE60311861D1 - Pyrazolochinoline mit immunmodulierenderwirkung - Google Patents

Pyrazolochinoline mit immunmodulierenderwirkung

Info

Publication number
DE60311861D1
DE60311861D1 DE60311861T DE60311861T DE60311861D1 DE 60311861 D1 DE60311861 D1 DE 60311861D1 DE 60311861 T DE60311861 T DE 60311861T DE 60311861 T DE60311861 T DE 60311861T DE 60311861 D1 DE60311861 D1 DE 60311861D1
Authority
DE
Germany
Prior art keywords
pyrazolochinoline
methods
heterocyclic compounds
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60311861T
Other languages
English (en)
Other versions
DE60311861T2 (de
Inventor
Ian Richard Matthews
Thomas Stephen Coulter
Chiara Ghiron
Chris James Brennan
Muhammed Kamal Uddin
Lars Olof Pettersson
Dorthe Da Graca Thrige
Philip Huxley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0203471A external-priority patent/SE0203471D0/xx
Priority claimed from SE0301299A external-priority patent/SE0301299D0/xx
Priority claimed from SE0301851A external-priority patent/SE0301851D0/xx
Application filed by Active Biotech AB filed Critical Active Biotech AB
Application granted granted Critical
Publication of DE60311861D1 publication Critical patent/DE60311861D1/de
Publication of DE60311861T2 publication Critical patent/DE60311861T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60311861T 2002-11-22 2003-11-21 Pyrazolochinoline mit immunmodulierender wirkung Expired - Lifetime DE60311861T2 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US42824002P 2002-11-22 2002-11-22
SE0203471A SE0203471D0 (sv) 2002-11-22 2002-11-22 Immunomodulatory compunds
SE0203471 2002-11-22
US428240P 2002-11-22
SE0301299A SE0301299D0 (sv) 2003-05-06 2003-05-06 Immunomodulatory compounds
SE0301299 2003-05-06
US48212203P 2003-06-25 2003-06-25
US482122P 2003-06-25
SE0301851 2003-06-25
SE0301851A SE0301851D0 (sv) 2003-06-25 2003-06-25 Immunomodulatory compounds
PCT/SE2003/001805 WO2004048378A1 (en) 2002-11-22 2003-11-21 Pyrazoloquinolines with immunomodulating activity

Publications (2)

Publication Number Publication Date
DE60311861D1 true DE60311861D1 (de) 2007-03-29
DE60311861T2 DE60311861T2 (de) 2007-11-22

Family

ID=32398347

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60311861T Expired - Lifetime DE60311861T2 (de) 2002-11-22 2003-11-21 Pyrazolochinoline mit immunmodulierender wirkung

Country Status (14)

Country Link
US (2) US7081456B2 (de)
EP (2) EP1813616B1 (de)
JP (1) JP2006509047A (de)
CN (1) CN100347173C (de)
AT (1) ATE353898T1 (de)
AU (1) AU2003279687A1 (de)
CA (1) CA2506524A1 (de)
DE (1) DE60311861T2 (de)
ES (1) ES2282693T3 (de)
HK (1) HK1086562A1 (de)
NO (1) NO20053018L (de)
NZ (1) NZ540081A (de)
RU (1) RU2328496C2 (de)
WO (1) WO2004048378A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60326639D1 (de) * 2002-12-16 2009-04-23 Active Biotech Ab Tetrazyklische immunmodulierende verbindungen
CA2519063C (en) 2003-03-14 2011-05-10 Avidex Limited Immunomodulating heterocyclic compounds
GB0325644D0 (en) 2003-11-04 2003-12-10 Avidex Ltd Immuno ihibitory pyrazolone compounds
AU2004322237B2 (en) 2004-08-09 2011-09-22 Medigene Ag Immunomodulating oxopyrrazolocinnolines as CD80 inhibitors
WO2008043072A2 (en) * 2006-10-05 2008-04-10 Biogen Idec Inc. Cd80 antagonists for treating neoplastic disorders
EP2676666A1 (de) * 2012-06-20 2013-12-25 Eidgenössische Technische Hochschule Zürich (ETH) Verbindungen zur Verwendung bei der Diagnose oder Therapie anfälliger atherosklerotischer Plaques
CN102977095B (zh) * 2012-12-03 2015-10-28 华东理工大学 吡唑并喹啉类化合物及其用途
US9809589B2 (en) * 2012-12-22 2017-11-07 Kbp Biosciences Co., Ltd. Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor
EP2883883A1 (de) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden
CN110698456B (zh) * 2019-11-06 2021-05-14 重庆医药高等专科学校 一种2,3-二氢硫代色烯-4-酮及其衍生物的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268516A (en) * 1978-10-11 1981-05-19 Pfizer Inc. [1]Benzothiopyrano[4,3-c]pyrazoles as immunoregulatory agents
US4312870A (en) * 1979-06-21 1982-01-26 Ciba-Geigy Corporation Pyrazoloquinolines
PH21213A (en) * 1984-10-26 1987-08-21 Fujisawa Pharmaceutical Co Benzene- and pyrazole- fused heterocyclic compound and pharmaceutical composition comprising the same
US4758427A (en) * 1985-08-08 1988-07-19 Ciba-Geigy Corporation Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone
JPH05505180A (ja) * 1990-02-02 1993-08-05 ザ ブーツ カンパニー ピーエルシー 治療薬
GB9002423D0 (en) * 1990-02-06 1990-04-04 Boots Co Plc Therapeutic agents
CN1069272A (zh) * 1991-08-02 1993-02-24 布茨公司 制备苯并吡或噻喃并吡唑的方法
AR006520A1 (es) * 1996-03-20 1999-09-08 Astra Pharma Prod Derivados de 2-arilpirazolisoquinolina y cinolinona y procedimiento para su preparacion.
US6642249B2 (en) * 2001-07-04 2003-11-04 Active Biotech Ab Immunomodulating compounds
SE0102404D0 (sv) * 2001-07-04 2001-07-04 Active Biotech Ab Novel immunomodulating compounds

Also Published As

Publication number Publication date
CN1729191A (zh) 2006-02-01
CA2506524A1 (en) 2004-06-10
RU2328496C2 (ru) 2008-07-10
JP2006509047A (ja) 2006-03-16
EP1813616A3 (de) 2007-08-08
US20060217411A1 (en) 2006-09-28
US20040116461A1 (en) 2004-06-17
ATE353898T1 (de) 2007-03-15
RU2005119639A (ru) 2006-01-20
NO20053018L (no) 2005-08-22
AU2003279687A1 (en) 2004-06-18
WO2004048378A1 (en) 2004-06-10
US7291612B2 (en) 2007-11-06
EP1813616A2 (de) 2007-08-01
EP1562944B1 (de) 2007-02-14
DE60311861T2 (de) 2007-11-22
CN100347173C (zh) 2007-11-07
US20050203118A9 (en) 2005-09-15
ES2282693T3 (es) 2007-10-16
NZ540081A (en) 2008-03-28
NO20053018D0 (no) 2005-06-20
HK1086562A1 (en) 2006-09-22
EP1813616B1 (de) 2013-03-27
US7081456B2 (en) 2006-07-25
EP1562944A1 (de) 2005-08-17

Similar Documents

Publication Publication Date Title
NO20053018D0 (no) Pyrazoloquinoliner med immunmodulerende aktivitet.
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
WO2012080284A3 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
BR0311343A (pt) Derivados de piridazina
TN2012000530A1 (en) Nitrogen heterocyclic compounds useful as pde10 inhibitors
WO2008045393A3 (en) Imidazo- and triazolo-pyridine compounds and methods of use therof
DE50306845D1 (de) Disubstituierte thiazolylcarboxanilide und ihre verwendung als mikrobizide
WO2009025839A3 (en) Phosphodiesterase 10 inhibitors
MX2007011848A (es) Antagonistas del receptor de procineticina i.
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
DK1725536T3 (da) Imidazolin-derivater med CB1-antagonistisk aktivitet
SE0102404D0 (sv) Novel immunomodulating compounds
PE20061080A1 (es) Compuestos derivados de piridotienopirimidina como inhibidores de fosfodiesterasa 4
MXPA04007019A (es) Agentes de diamina para control de plagas de invertebrados.
WO2005009951A3 (en) Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
WO2006079720A8 (fr) Nouveaux derives d1oximes heterocycliques, leur procede de preparation et leur utilisation comme agents hypoglycemiants et hypoli pemiants
ATE425164T1 (de) Tetrazyklische immunmodulierende verbindungen
EA200500542A1 (ru) Тиазол-(би)циклоалкилкарбоксанилиды
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
DE602004029383D1 (de) Isten und antagonisten
NO20076676L (no) Nye 8-sulfonyl-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition